Therapy News and Research

RSS

SAGE to launch European Edition of 'Foot & Ankle Specialist'

SAGE is to launch Foot & Ankle Specialist - European Edition from February 2011. The journal will be an international edition of Foot & Ankle Specialist (FAS), a bimonthly controlled circulation journal launched in 2008 publishing peer-reviewed clinical information for foot and ankle caregivers.

18 Aug 2010

AMT's MAA for LPLD gene therapy product Glybera on schedule

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today announced that the Marketing Authorisation Application (MAA) for Glybera(R) remains on schedule following meetings with the European Medicine Agency (EMA) concerning the Day 120 List of Questions. The company is confident that Glybera(R), a gene therapy product for lipoprotein lipase deficiency (LPLD), remains on track for a regulatory decision by mid-2011.

18 Aug 2010

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

One of the most tantalizing developments in anti-cancer therapy over recent years has been the advent of targeted treatments, which have proven highly effective in holding aggressive cancers at bay in certain patients, although typically only for a limited period of time.

18 Aug 2010

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

Researchers from this international study found that patients with chronic hepatitis B virus (HBV) infection who received at least 3 years of cumulative entecavir (antiviral) therapy achieved substantial histologic improvement and regression of fibrosis or cirrhosis. Full details of the study appear in the September issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

18 Aug 2010

NACTN receives grant to expand spinal cord injury research

The United States Department of Defense (DoD) awarded the Christopher & Dana Reeve Foundation a $5.4 million grant to support the expansion of translational research to find treatments for military men and women with spinal cord injuries.

18 Aug 2010

Alliance HealthCare Services offers to exchange series B senior notes due 2016

Alliance HealthCare Services, Inc.,a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced today that it has completed its offer to exchange (the "Exchange Offer") up to $190 million aggregate principal amount of its 8.00% series B senior notes due 2016 which have been registered under the Securities Act of 1933, as amended, for any and all of its outstanding 8.00% senior notes due 2016 which were issued in a private placement (the "Private Notes").

18 Aug 2010

Adult stem cells associated with poor prognosis of cancer: Research

Adult stem cells that are vital for airway repair in the lung but that persist in areas where pre-cancerous lesions are found are associated with a poor prognosis in patients who develop cancer, even those with early stage disease, researchers at UCLA's Jonsson Comprehensive Cancer Center have found.These adult stem cells are found in repairing areas after injury and also are found in pre-cancerous areas, suggesting that these cells may mutate and become cancer causing stem cells, making them a potential cell-of-origin for lung cancer and a possible target for prevention strategies and new targeted therapies.

18 Aug 2010

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

Cryo-Cell International, Inc., one of the largest and most established leaders in stem cell innovation, today announced a research and development collaboration agreement with Monash University in Australia. The partnership will allow scientists from the University's Centre of Inflammatory Diseases to conduct pre-clinical studies using Cryo-Cell's proprietary C'elle menstrual stem cell technology (MenScs) to identify potential future therapies to treat autoimmune diseases such as multiple sclerosis.

18 Aug 2010

CaridianBCT releases version 6.0 of Trima Accel Automated Blood Collection System

CaridianBCT, the leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, announced the global release of the Trima Accel® Automated Blood Collection System Version 6.0. The latest version of the flagship automated blood collection platform provides streamlined operations and potentially increased cost savings for customers worldwide.

18 Aug 2010

NCI grants SBIR award to MabVax Therapeutics

MabVax Therapeutics, Inc., a privately held clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer, announces that it has received a Small Business Innovation Research Grant (SBIR) from the National Cancer Institute (NCI) under the agency's Streamlined Non-competing Award Procedures (SNAP).

18 Aug 2010

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate is ZC-701, a novel fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease.

18 Aug 2010

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

17 Aug 2010

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Merck is pleased to announce that New Brunswick, Nova Scotia and Alberta are the first provinces in Canada to reimburse SIMPONI(golimumab) for the treatment of three different rheumatic conditions. SIMPONI, a subcutaneous anti-tumor necrosis factor therapy, is now reimbursed by the drug formularies of these three provinces for people living with moderately to severely active rheumatoid arthritis, moderately to severely active psoriatic arthritis and active ankylosing spondylitis.

17 Aug 2010

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

Today, Pisgah Labs, Inc. received a Notice of Allowance from the United States Patent and Trademark office for an important new technology patent addressing global stability problems of thyroid hormone drugs.

17 Aug 2010

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Palatin Technologies, Inc. today announced positive results of a Phase 1 clinical trial of subcutaneously administered bremelanotide, its melanocortin agonist drug candidate for treatment of male erectile dysfunction (ED) and female sexual dysfunction (FSD). The results demonstrate that with subcutaneous administration consistent therapeutic blood plasma levels can be obtained without sustained clinically significant blood pressure effects and support the continued development of bremelanotide.

17 Aug 2010

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.

17 Aug 2010

Natick VNA offers checklist to help patients make informed choice of home health care provider

Home from the hospital already? As stays for hospital patients grow progressively shorter, even for procedures as serious as repairing a brain aneurysm or inserting a pacemaker, patients' need for highly skilled nursing care at home is growing. Indeed, every week, thousands of these patients are referred to home health care services.

17 Aug 2010

Smith & Nephew's Renasys EZ system infringes KCI's European patent

Kinetic Concepts, Inc. today announced that the German District Court in Mannheim has found that Renasys canisters and foam dressings used with Smith & Nephew plc's Renasys EZ system infringe KCI's German counterpart of European patent EP 0 853 950 patent relating to negative pressure wound therapy.

17 Aug 2010

NSF awards Georgia Institute of Technology $3 million for stem cell bio-manufacturing research program

The National Science Foundation (NSF) has awarded $3 million to the Georgia Institute of Technology to fund a unique research program on stem cell bio-manufacturing. The program is specifically focused on developing engineering methods for stem cell production, in order to meet the anticipated demand for stem cells. The award comes through the NSF's Integrative Graduate Education and Research Traineeship (IGERT) Program, which supports innovation in graduate education in fields that cross academic disciplines and have broad societal impact.

17 Aug 2010

Ancient discovery holds key to joint tissue regeneration

Osteoarthritis is a crippling disease worldwide, with an estimated eight million sufferers in the UK alone. It has been described as like "wearing a suit of rusty armour," with unrelenting, razor-like pain.

17 Aug 2010

Therapy News and Research

SAGE to launch European Edition of 'Foot & Ankle Specialist'

AMT's MAA for LPLD gene therapy product Glybera on schedule

Study shows increase in IL-6 secretion can reduce Tarceva sensitivity to treat lung tumor cells

Long-term entecavir therapy suppresses HBV DNA, normalizes ALT and improves liver histology

NACTN receives grant to expand spinal cord injury research

Alliance HealthCare Services offers to exchange series B senior notes due 2016

Adult stem cells associated with poor prognosis of cancer: Research

Cryo-Cell International collaborates with MNSH to identify potential therapy for autoimmune diseases

CaridianBCT releases version 6.0 of Trima Accel Automated Blood Collection System

NCI grants SBIR award to MabVax Therapeutics

BioMarin Pharmaceutical acquires ZyStor Therapeutics, furthers development of ZC-701 for Pompe disease

Long-term Entecavir therapy reverses fibrosis and cirrhosis in chronic hepatitis B patients

Merck's SIMPONI anti-TNF therapy now reimbursed in New Brunswick, Nova Scotia and Alberta

Pisgah Labs receives Notice of Allowance for new patent relating to thyroid hormone drugs

Palatin reports positive results from bremelanotide Phase 1 trial for sexual dysfunction

Xenon Pharmaceuticals commences phase 2 clinical trial of XEN402 therapy for PHN

Natick VNA offers checklist to help patients make informed choice of home health care provider

Smith & Nephew's Renasys EZ system infringes KCI's European patent

NSF awards Georgia Institute of Technology $3 million for stem cell bio-manufacturing research program

Ancient discovery holds key to joint tissue regeneration

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News